Eutecma's Tempaid buy pairs reusable bulk shippers with last-mile mailers as smaller, more frequent refrigerated shipments reshape demand.
|Articles|June 4, 2015
- Pharmaceutical Commerce - July/August 2015
AmerisourceBergen will build three new DCs; Cardinal tucks in Harvard Drug Corp.
Olive Branch, MS; Shakopee, MN; and Newburgh, NY are the designated ABC sites
Advertisement
AmerisourceBergen has announced that it will build three new distribution centers, in the South, Midwest and Northeast to accommodate customer growth and technology capabilities. Construction will start this summer and be complete in 18-24 months. These investments are part of a broader service capability, says the company, to:
•
Increase distribution capacity and facilities that support innovation
•
Advance customer issue monitoring and resolution tools
•
Improve customer communication technology.
The company’s drug-distribution unit currently has 25 DCs across the country; there are additional facilities in its specialty group, and facilities acquired this spring through its acquisition of MWI Veterinary. A new facility opened in Columbus, OH, last December, and another facility, in Orlando, FL, was rebuilt last year. ABC handles 35% of US drug distribution.
"We grow when our customers grow, so it's no surprise that our goal is to help successfully execute the patient-focused strategies of the manufacturers, providers, pharmacists and retailers who we support," said Bob Mauch, EVP and president of AmerisourceBergen Drug Corp.
Articles in this issue
about 11 years ago
Manufacturers can support the ICD-10 transitionabout 11 years ago
Building a cold-chain data networkabout 11 years ago
Biotech manufacturing capacity is expanding in North Americaabout 11 years ago
2015 PDMA Sharing Conferenceabout 11 years ago
The Phase III pricing experimentabout 11 years ago
Moving the needle on diabetesabout 11 years ago
Product launch--the 21st-century wayabout 11 years ago
Get better at managing clinical trial financialsAdvertisement
Related to this article
Twenty-six manufacturers now hold most-favored-nation agreements, and the commitments attached to the pricing terms may matter more than the prices themselves.
Ed Schoonveld examines the uncertainty surrounding President Trump's MFN drug pricing agreements, stalled GENEROUS, GLOBE and GUARD proposals, and their ripple effects on ex-US drug launches.
Waltz Health and Fresenius Kabi will offer three biosimilars through a direct-to-payer model that bypasses traditional wholesaler and PBM rebate channels.
HDA's Kala Shankle says a federal licensure baseline could bring real efficiency gains for wholesale distributors and 3PLs, but only if state requirements align and every stakeholder moves on the same timeline.
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
As patient expectations continue to evolve, brick-and-mortar pharmacy’s path forward lies in combining trusted, face-to-face care with the efficiency and convenience patients increasingly value.
Copeland's Dickson buy adds cloud-native monitoring as the pharma cold chain moves toward continuous visibility to meet rising regulatory demands.
Advertisement
Advertisement